Zydus Cadila Healthcare has received the final approval from the United States Food & Drug Administration (USFDA) to market Fluocinonide cream USP, 0.1%.
As per the company's press release, the drug is used for the treatment of variety of skin conditions (like psoriasis, eczema, dermatitis, allergies and rash). The medicine would be manufactured at its topical manufacturing unit at Ahmedabad, Gujarat.
With an additional feather in Cadila Heathcare's cap, the Group now has a total of 279 approvals and has filed over 386 ANDAs (Abbreviated New Drug Applications) since the commencement of the filing process in FY 2003-04.
The announcement was released after market hours yesterday, 11 February 2020.
Shares of Cadila Healthcare fell 1.51% to close at Rs 274.60 on BSE on Tuesday, 11 February 2020.
Cadila Healthcare is a pharmaceutical company based out of India. It is a global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 25,000 people worldwide and aspires to be a research-based pharmaceutical company by 2020.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app